Greenwich Lifesciences, Inc. (GLSI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$15.95+2.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GLSI
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 20.6 | 17.2 | 13.0 | 7.7 | 6.5 | 3.6 | 1.1 |
| Operating Income | (22.7) | (19.4) | (16.0) | (9.3) | (8.0) | (4.6) | (1.9) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 0.2 | 0.1 | 0.2 | 0.4 | 0.2 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (22.9) | (19.4) | (15.8) | (8.9) | (7.8) | (4.6) | (1.9) |
| Per Share | |||||||
| Basic EPS | (1.57) | (1.43) | (1.21) | (0.69) | (0.61) | (0.35) | — |
| Diluted EPS | (1.57) | (1.43) | (1.21) | (0.69) | (0.61) | — | — |
| Basic Weighted Avg Shares | 14.6 | 13.5 | 13.0 | 12.8 | — | — | — |
| Diluted Weighted Avg Shares | 14.6 | 13.5 | 13.0 | 12.8 | 12.9 | — | — |
| Supplemental | |||||||
| EBIT | (22.7) | (19.4) | (16.0) | (9.3) | (8.0) | (4.6) | (1.9) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.